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Summary The present study evaluated serial serum measurements oftissue polypeptide-specific antigen (TPS) in comparison with prostate-
specific antigen (PSA) for assessment of tumour progression in patients with advanced prostate cancer receiving intermittent androgen
suppression therapy (IAS). Twenty-three men were recruited into an IAS trial consisting of an initial 8 months of androgen suppression,
followed by cycles of treatment cessation and resumption of therapy upon increases of PSA > 20 ng ml-' to prolong the hormone
responsiveness of the tumour cells. Periods of androgen suppression resulted in reversible reduction in serum testosterone (< 1.8 nmol l-1)
and PSA (< 4 ng ml-') and decreases in tumour volume (mean reduction for first cycle 24 ± 10%), indicating partial growth arrest and apoptotic
regression of the tumours. In contrast to PSA values, non-specifically elevated TPS values were found in 8 of 23 patients. In 15 of 23 patients,
TPS fell during periods of apoptotic tumour regression and increased simultaneously with testosterone and preceded the increases in PSA by
2 months during the period of treatment cessation. Although TPS represents a highly sensitive marker of tumour proliferation in this IAS
clinical model of controlled tumour regression and regrowth, its low specificity compared with PSA limits its usefulness to monitoring of
prostate cancer patients with proven absence of non-specific elevations of this marker.
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Prostate cancer has become the most common newly diagnosed
cancer in men in recent years (Kozlowski and Grayhack, 1996).
When there is tumour involvement outside the prostatic capsule,
this disease is ultimately incurable in most cases. Palliative treat-
ment consists of hormonal manipulation by orchidectomy or
oestrogens, LHRH analogues and steroidal or non-steroidal anti-
androgens to deprive the cancer cells of androgenic stimulation
(Kozlowski and Grayhack, 1996). After primary hormonal abla-
tion by orchidectomy, the concept of maximal androgen blockade
by combining anti-androgen and LHRH analogues has been prop-
agated as means to improve survival ofpatients with disseminated
prostate cancer (Denis, 1995). The androgen-dependent tumour
cells exhibit apoptotic regression in a high percentage of cases
upon this treatment. Unfortunately, this high initial response is
temporary because surviving tumour cells progress to an
androgen-independent growth condition (Bruchovsky et al, 1990).
All attempts of a cytotoxic therapy for these androgen-resistant
tumours have been met with limited success and have failed to
result in significant prolongation ofthe low survival rates (Yagoda
and Petralyk, 1993; Theyer and Hamilton, 1994).
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A new clinical concept relies on the possibility of intermittent
androgen suppression (IAS) to keep tumorigenic stem cells in an
androgen-responsive state. The regrowing tumours have been
shown to respond to androgen withdrawal for several cycles and
IAS has been shown to result in improved quality of life and
possible prolonged survival in pilot clinical trials (Akakura et al,
1993). Monitoring of serum testosterone and prostate-specific
antigen (PSA) has been used in experimental animal models and
clinical studies for the determination of the androgen-free treat-
ment period by defining the level of tumour regrowth. However,
the expression of PSA is androgen dependent, and therefore this
marker may not adequately reflect tumour mass during androgen
withdrawal therapy (Miller et al, 1992).
In the present study, we have investigated the tumour marker
tissue polypeptide-specific antigen (TPS) in comparison with
serum testosterone and PSA in a group of patients receiving IAS
for assessment of the onset of tumour regrowth. The TPS assay
involves the use of the M3 monoclonal antibody, recognizing a
cell proliferation-associated epitope of the tissue polypeptide
antigen (TPA; Bormer, 1994). TPA and TPS have been described
as useful markers for a range ofdifferent tumours and in particular
TPS as a sensitive indicator of tumour response (Bjorklund,
1980). IAS constitutes a clinical model of controlled apoptotic
tumour regression and regrowth, and TPS can be tested for its
possible correlation with proliferation/tumour cell damage in
comparison to responses observed in testosterone, PSA and
tumour volume.
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PATIENTS, MATERIALS AND METHODS
Patients and treatment schedule
All patients gave written informed consent according to local
regulatory requirements. Between June 1993 and March 1995, all
patients with disseminated adenocarcinoma of the prostate
fulfilling the inclusion criteria ofhistologically confirmed tumour,
stage > T3, performance status 0 or 1, no pretreatmentby hormone
ablation or chemotherapy and PSA > 6 ng ml-1 were recruited into
a non-randomized open intermittent androgen-suppression trial
consisting of an initial 8-month course of androgen suppression
('S'-phase; LHRH antagonist Zoladex and cyproterone acetate),
followed by treatment cessation ('C'-phase) and resuming of the
therapy upon increases of PSA > 20 ng ml-'. Serum testosterone
and PSA were monitored monthly, and patients failing to show
normalization of PSA (< 4 ng ml-') after 24 and 32 weeks of
androgen ablation were excluded. Loss ofandrogen dependence is
defined as three sequential increases in PSA above normal range
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include digital rectal examination, transrectal sonography and
yearly chest radiography and bone scans.
Laboratory measurements
A blood sample was taken from each patient before treatment and
at monthly intervals thereafter and stored at -20°C until analysis.
Blood urea nitrogen (BUN), creatinine, GOT, GPT, gamma-GT
and peripheral blood counts of erythrocytes, leucocytes and
thrombocytes were measured in all patients at the beginning ofthe
trial. Serum testosterone was measured using a microtitre plate
ELISA (Biomar Diagnostics, Marburg, Germany) according to the
manufacturer's instructions (normal range 8.3-41.6 nmol 1-';
detection limit 0.35 nmol 1-'). PSA was determined in
the microparticulate enzyme immunoassay with 0 ng ml-' and
10 ng ml' standards (MEIA AxSYM PSA assay; Abbott, USA).
TPS (Beki Diagnostics, Bromma, Sweden) was determined with
an ELISA consisting of polyclonal horse antibodies plastic beads
and the M3 monoclonal antibody, the results of which correlate
well with the TPS-IRMA test. The standard curve was established
with samples containing 0-2500 U ml-' TPA, and the assay was
performed as automated bead enzyme immunoassay (Cobas Core
Roche analyser). According to the manufacturer's instructions, a
cut-off value of 80 U l-1 was defined for TPS in a healthy control
group of 195 probands (95% percentile).
Statistics
Non-parametric statistical analysis was used. Differences between
two independent groups were determined with the Mann-Whitney
U-test. Spearman rank-order correlation coefficients were calcul-
ated for a comparison of tumour-specific and non-specific TPS
groups. A P-value < 0.05 was regarded as statistically significant.
All calculations were done using the Statistica software package
(Statsoft, Tulsa, OK, USA).
RESULTS
Blood samples from 23 patients were obtained monthly and tumour
response following IAS was monitored using PSA, serum testos-
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Intermittent androgen suppression cycles resulted in a reversible
reduction in serum testosterone (< 1.8 nmol 1-') and a rapid decline
ofPSA to baseline levels (< 4 ng ml-'), followed in each individual
patient by a slow increase in PSA upon cessation of the anti-
androgenic therapy (C1-C7; > 15 ng ml-1) and by normalization
of serum testosterone levels (> 6 nmol 1-1) consistent with tumour
regression and subsequent reappearance of hormone-responsive
PSA-positive tumour cells (Figure A-C). According to the defini-
tion ofinclusion criteria, all patients responded to anti-androgenic
therapy, as measured by their serum testosterone and PSA profiles.
All patients showed a decrease in tumour volume, as measured by
ultrasonography: 32.5 ± 4.6 ml before therapy and 24.7 ± 3.9 ml
after androgen ablation (median values 28 and 20.6 ml respec-
tively). In 15 of 23 patients, TPS closely matched the time course
of PSA, whereas in 8 of 23 patients significant TPS elevations
could be measured during baseline values ofboth testosterone and
PSA (S2-S8), indicating tumour marker increases due to mecha-
nisms not associated with tumour growth and limiting in this study
the specificity of TPS assays to 65%. In the TPS/PSA-concordant
group the first significant increase in TPS was observed at C2,
followed by a significant increase in PSA at C4, 3 months later.
The TPS/PSA-concordant group, however, exhibited an increase
in testosterone reappearance 1 month earlier (C2) than the diver-
gent group (C3). No increased production and/or release of TPS
was observed during androgen suppression-induced apoptotic
regression, which was most likely to occur within days and weeks
following initiation of treatment (S2-S4).
DISCUSSION
Adenocarcinoma of the prostate in advanced stage is treated by
surgical and/or anti-androgenic hormone ablation aiming at elimi-
nation ofproduction, metabolism and usage of androgens as far as
possible (Kozlowski and Grayhack, 1996). Despite very high
initial responses to androgen suppression, in most cases the
tumours recur as highly androgen-resistant and chemoresistant
tumours within several years and are not particularly amenable to
further treatment (Yagoda and Petralyk, 1993). A long-debated
new clinical concept, namely intermittent androgen suppression
(IAS), tries to prolong the hormone dependency of the tumour
cells, and possibly survival, by allowing for a limited regrowth of
hormone-sensitive cells between suppression treatment cycles
(Bruchovsky et al, 1995). Support for this treatment modality
comes from experimental animal models and clinical pilot trials
that demonstrate significant increases in time to progression to
androgen insensitivity of tumours (Akakura et al, 1993). An open
clinical trial of intermittent androgen suppression was initiated at
our institution to study progression time to androgen insensitivity
and quality of life and, additionally, its use as a unique model of
controlled in vivo tumour proliferation capable of proving the
tumour specificity of markers like proliferation-associated TPS
and others. In this case, tumour regression and regrowth is docu-
mented by ultrasonic measurements, PSA production and indi-
rectly by availability of testosterone.
Although PSA is a sensitive marker ofprostate-related diseases,
its production depends on androgens, therefore possibly compli-
cating its use in androgen suppression trials and advanced
androgen-insensitive tumours (Leo et al, 1991; Miller et al, 1992).
An alternative technique to detect the progression of different
tumours relies on the detection oftissue polypeptide antigen (TPA)
released by cycling cells during S- and G2 phase (Marino et al,
1992). The M3 monoclonal antibody, which recognizes a prolifer-
ation-associated epitope of TPA, is used for the ELISA or RIA
measurement of the polypeptide-specific antigen (TPS) and has
been demonstrated recently to identify TPS as a cytokeratin 18
derivative (Bormer, 1994). TPS is detectable in non-malignant
disorders, such as infections, autoimmune disease and inflamma-
tory processes and in patients with renal and hepatic impairment
(Bormer, 1994). TPS assays have been used in various human
malignancies, and its expression has been linked to poor prognosis
and metastasis (Marino et al, 1992; Komek et al, 1995; Plebani et
al, 1995). In prostate cancer, this tumour marker discriminates
benign prostatic hypertrophy from tumour, and increasing serum
concentrations of TPS have been detected with increasing tumour
grade (Marrink et al, 1993; Tarle et al, 1993a, b, 1994). In contrast
to the role of TPS as a significant prognostic parameter for
different tumours, a poor correlation was found with tumour
shrinkage or tumour growth during chemotherapy for non-small-
cell lung carcinoma (NSCLC) patients, questioning its direct
linkage to tumour proliferation (Plebani et al, 1995).
A detailed assessment of TPS as a cell proliferation-associated
marker is expected to be feasible in a clinical situation, in which
the proliferative state of a tumour is controlled by specific treat-
ment modalities and monitored by independent markers. This
model is fulfilled in clinical IAS consisting of alternating periods
oftumoursuppression and controlledregrowth guidedby PSA and
testosterone serum determinations. In the present study, we inves-
tigated the monthly longitudinal variations in testosterone, PSA
and TPS in 23 patients with advanced prostate cancerparticipating
in an IAS trial. In correspondence with the protocol, all patients
showed a marked decline in serum testosterone in response to
suppression therapy, with low values during treatment and rapid
recovery to pretreatment values upon cessation of the androgen
blockade (CI-C2). PSA dropped to < 4 ng ml- upon hormone
suppression in each case and a significant increase could be
observed 4 months after discontinuation of androgen ablation
(C4). All recurring tumours proved to be PSA positive for these
first treatment cycles, and these findings taken together with
declining tumour volumes indicate apoptotic tumour regression
and regrowth of hormone-responsive, PSA-positive tumours. The
moderate reduction in tumour volumes indicates that the decline in
PSA is partly caused by decreased production of PSA during
suppression in addition to the actual loss oftumour cells.
As tumour regression, low testosterone and PSA values were
found in all patients upon initiation oftreatment, the high levels of
circulating TPS observed during androgen suppression (SI-S8) in
8 of23 patients are most likely derived from non-malignant prolif-
erative processes. Check of clinical status and history as well as
biochemical parameters creatinine, blood urea nitrogen (BUN),
liver enzymes and leucocyte counts revealed no specific causes for
TPS elevations in these individual patients. None ofthese patients
could be identified as being at high risk for showing TPS eleva-
tions for known reasons of non-malignant TPS production, and
any small contribution oftumour-linked TPS production cannot be
differentiated against this high-TPS background. Such a low sensi-
tivity (65%) forTPS tumourmarker studies has been demonstrated
in other studies previously (Bormer, 1994; Plebani et al, 1995). In
the subgroup of patients (15 of 23) showing apparantly tumour-
associated TPS production, the TPS increases became obvious
very early at the second observation after cessation of the
androgen blockade (C2), proving TPS as ahighly sensitive marker
of tumour progression. The absence of TPS elevations during
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apoptotic regression of the tumours indicates that TPS is not
simply released during cell death but actively produced and
released during proliferative phases oftumour growth. Because of
the monthly intervals of TPS determinations, an initial release of
TPS within several days may have been missed, but this is unlikely
as tumour volumes decreased for several months and TPS remains
in the circulation for extended periods. In conclusion, IAS demon-
strates TPS to constitute a highly sensitive but not tumour-specific
proliferation-associated parameter, suited for monitoring disease
progress in tumour patients in the absence of non-malignant
causes of TPS elevations. Non-specific increases of TPS serum
concentrations may be very difficult to exclude in routine
screening or other clinical settings and tumours for which indepen-
dent parameters, such as PSA, in IAS are not available for the
assessment of tumour response.
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